BPH: Epidemiology and comorbidities

American Journal of Managed Care

Volumn 12, Issue SUPPL. 5, 2006, Pages

  McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ENZYME INHIBITOR; STEROID 5ALPHA REDUCTASE;

AGING; ARTICLE; AUTOPSY; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; ERECTILE DYSFUNCTION; GROUPS BY AGE; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SYSTEMATIC REVIEW; UNITED STATES; URINE FLOW RATE; ADULT; AGE DISTRIBUTION; AGED; DRUG ANTAGONISM; HEALTH; IMPOTENCE; MALE; MIDDLE AGED; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES COMPLICATIONS; ENZYME INHIBITORS; HUMANS; IMPOTENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PROSTATIC HYPERPLASIA; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE; WORLD HEALTH;

EID: 33645956542     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530-547.
2. Wei JT, Calhoun E, Jacobsen SJ. Urologic Diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173:1256-1261.
3. Oesterling JE. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl. 1996;6:67-73.
4. Chapple CR. Selective α1-adrenoreceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol. 1996;29:129-144.
5. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637-649.
6. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47: 824-837.
7. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479.
8. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85-89.
9. Jacobsen SJ, Jacobsen DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158:481-487.
10. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol. 1997;31:272-280.
11. Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed "benign prostatic hyperplasia," and their effect on quality of life in a community-based survey of men in the UK. BJU Int. 1999;83:410-415.
12. Collins MM, Barry MJ, Bin L, Roberts RG, Oesterling JE, Fowler FJ. Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physicians. J Gen Intern Med. 1997;12:224-229.
13. O'Leary MP. LUTS, ED, QOL: alphabet soup or real concerns to aging men? Urology. 2000;56(5 suppl 1): 7-11.
14. Lepor H, Lowe FC. Evaluation and nonsurgical management of benign prostastic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's Urology. 8th ed. Philadelphia, Pa: WB Saunders Co; 2002:1337-1378.
15. 1A-adrenergic antagonist. Urology. 1998;51:861-872.
16. Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct alpha 1-adrenoreceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994;113:723-728.
17. 1d-subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000;85(suppl 2):6-11.
18. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant α1-adrenoreceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995;288: 201-207.
19. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int. 2005;95(suppl 4): 29-36.
20. Narayan P, O'Leary MP, Davidai G. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res. 2005;5:237-245.
21. McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.
22. McConnell JD. Benign prostatic hyperplasia. Hormonal treatment. Urol Clin North Am. 1995;22: 387-400.
23. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol. 1995;29:7-12.
24. Jepsen JV, Bruskewitz RC. Comprehensive patient evaluation for benign prostatic hyperplasia. Urology. 1998;45:64-69.
25. Lloyd-Jones DM. Evans JC, Larson MG, Levy D. Treatment and control of hypertension in the community: a prospective analysis. Hypertension. 2002;40:640-646.
26. Vasan RS, Beiser A, Seshadri S, et al. Residual life-time risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003-1010.
27. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol. 2004;172(4 pt 1):1390-1393.
28. National Diabetes Information Clearinghouse (NDIC). National Diabetes Statistics. NIH Publication No. 06-3892. November 2005. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics. Accessed November 4, 2005.
29. Klein R, Klein BE, Moss SE. Ten-year incidence of self-reported erectile dysfunction in people with long-term type-1 diabetes. J Diabetes Complications. 2005;19:35-41.
30. American Heart Association. Metabolic syndrome. 2005. Available at: www.americanheart.org/presenter. jhtml?identifier=4756. Accessed October 20, 2005.
31. Blouin K, Despres JP, Couillard C, et al. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism. 2005;54:1034-1040.
32. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62:27-33.
33. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
34. Nicolosi A, Glasser DB, Moreira ED, Villa M; Erectile Dysfunction Epidemiology Cross National Study Group. Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res. 2003;15: 253-257.